SHENZHEN, China, Sept. 9, 2026 /PRNewswire/ — Commemorating BGI Group’s 27th anniversary, BGI Genomics today introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio at the 2026 Global New Product Launch Event. Grounded in over two decades of population-scale genetic discoveries, the launch marks a decisive transition from traditional, reactive diagnostics to continuous, predictive health management across the entire human lifecycle.
By bridging high-throughput multi-omics, massive cohort data, and self-evolving artificial intelligence, the Digital Life Twin framework cross-references routine annual health checkup metrics with population-level distribution patterns from large healthy cohorts. The model condenses complex multi-system indicators into quantifiable health indices to generate an individual’s baseline profile.
Jiang Xiaosen, General Manager of the Biological Intelligence Solutions Center at BGI Genomics, emphasized that mapping the full biological lifecycle establishes an actionable baseline, enabling clinicians and individuals to catch subclinical shifts well ahead of conventional clinical diagnosis. This fundamental pivot moves modern medicine from downstream reaction to early risk prediction, dynamic biological simulation, and personalized care.
At the core of the launch is the Life Index system and the upgraded i99 Smart Health platform. The upgraded i99 Smart Health platform, powered by global cohorts and cloud AI, deploys the 133111i testing framework. It converts multi-dimensional data from epigenetics, methylation, pharmacogenomics, lipidomics, metabolic profiles, cell atlases, and medical imaging. The data is turned into actionable Life Index wellness scores, mapping individual trajectories against universal population baselines.
On the hardware front, the Huo-Yan intellectual integration-powered i3 Smart Cabin™ serves as a compact health terminal occupying just two square meters. Equipped with multimodal intelligent sensors, it conducts non-invasive assessments across facial aging, vision, hearing, cognition, and physical constitution, generating a clinical-grade digital report in ten minutes. Tailored for urban business districts, hospitals, and community clinics, the terminal translates complex biological metrics into clear, actionable health insights for everyday consumers.
Jiang highlighted an obesity management case in which the platform moved beyond oversimplified “diet and exercise” guidance. By pinpointing the patient’s genetic appetite drivers, blunted satiety response, gut dysbiosis, and pharmacogenomic drug responses, the system validated the power of AI-driven, highly personalized precision interventions over generic lifestyle recommendations.
Huang Hui, Head of Genetic Testing Products, introduced the Global Family Heritage Initiative, an exclusive flagship whole-genome solution that bridges family members through multigenerational genomic data. The program enables households to uncover hidden hereditary risks early, tailor preventive interventions across life stages, and transform fragmented medical histories into an enduring biological safeguard for the entire lineage. Combining 10X long-read and 40X short-read sequencing, the complementary approach maximizes data completeness, read length, and accuracy. Backed by personalized genetic counseling, the program delivers an enduring health archive spanning oncology risks, chronic conditions, and telomere aging metrics, establishing a multi-generational biological asset for family health protection.
Tailored to diverse demographics and health goals, the WGLIFE series features a five-tier lineup: Fun, Discovery, Pioneer, Smart, and Flagship. Each tier steps up in sequencing depth, clinical reporting, and end-to-end support—evolving from fun genetic traits and lifestyle insights into actionable health risks, personalized medication guidance, and comprehensive preventive care to meet users wherever they are.
BGI Genomics also expanded its BIOAGE molecular aging series into three distinct tiers: Standard, Smart, and Flagship. The portfolio scales from foundational biological age and aging rate assessments to deeper chronic disease risk profiling. At the top tier, the upgraded BIOAGE Flagship Edition uses cell-free DNA methylation profiling to analyze signals from six vital organs and eight immune cell subsets. It combines biological age, organ health, immune status, chronic disease risks, and environmental exposures into a single molecular profile, enabling regular re-testing and long-term trend tracking for proactive health management.
Anchored by the Life Index system and built on precise risk stratification and systematic health assessments, this model connects upstream to BGI Genomics’ full portfolio of multi-omics tests and interventions while empowering downstream healthcare providers and health management centers.
To accelerate global clinical adoption, BGI Genomics finalized strategic partnerships with leading medical centers and health management organizations during the event. These collaborations will validate the Life Index framework across diverse clinical and community settings, establishing a closed-loop model built on measurement, evaluation, intervention, and long-term tracking.
Through these coordinated software, hardware, and diagnostic rollouts, BGI Genomics continues to advance its mission of bringing laboratory-grade life sciences into daily wellness, equipping individuals and families worldwide with scalable, lifelong health stewardship.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen, China, is the world’s leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions and involve more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.